[Possible relation between viruses and oromaxillofacial tumors. I. Demonstration of herpes antigens and anti-herpes antibodies]. / Relations possibles entres virus et tumeurs bucco-maxillo-faciales. Note I. Mise en évidence d'antigènes herpétiques et d'anticorps anti-herpétiques.

Herpes virus type 1 and 2 antigens were detected in cells originating from malignant tumors with oromaxillofacial localization. A higher incidence of type 1 antigens was noted, as compared to the type 2. Investigated antigens were detected more frequently in the tumors of ectodermal origin. Antiherpesvirus FC antibodies were found in 74.5% of the tumor bearing subjects, but only in 22.3% of the controls.

[Possible relation between viruses and oromaxillofacial tumors. IV. Presence of the herpes antigen and anti-herpes antibodies in patients with tumors of the parotid gland]. / Relations possibles entre virus et tumeurs bucco-maxillo-faciales. Note IV. Présence de l'antigène herpétique et des anticorps anti-herpétiques chez des malades porteurs de tumeurs de la glande parotide.

The presence of herpesvirus antigen and of antiherpesvirus antibodies was detected in 46% and in 36.3%, respectively, of the patients bearing parotid gland tumors. Very high titers of antiherpesvirus antibodies were found in 70.6% of the patients with nasopharyngeal carcinoma.

[Possible relation between viruses and oromaxillofacial tumors. III. Demonstration of the SV40 antigen and anti-SV40 antibodies in patients with tumors of the parotid gland]. / Relations possibles entre virus et tumeurs bucco-maxillo-faciales. Note III. Mise en évidence de l'antigène SV40 et des anticorps anti-SV40 chez des malades ayant des tumeurs de la glande parotide.

SV40 antigen was detected in 7 of 13 malignant tumors developed in the head and neck region. Specific complement fixing antibodies were found in all the patients with the SV40 antigen present in the parotid gland tumoral cells. Incidence of the anti-SV40 complement fixing antibodies in parotid gland tumor bearing patients was of 69.6%.

[Possible relation between viruses and oromaxillofacial tumors. II. Research on the presence of the SV40 antigen and specific antibodies in patients with oromaxillofacial tumors]. / Relations possibles entre virus et tumeurs bucco-maxillo-faciales. Note II. Recherches sur la présence de l'antigène SV40 et des anticorps spécifiques chez des malades porteurs de tumeurs bucco-maxillo-faciales.

SV40 antigen was detected on sections through malignant oromaxillofacial tumors in 47.8% of the cases, with a higher incidence among the epithelium originating tumors. Anti-SV40 CF antibodies were detected in 83.6% of the examined subjects with cancer, but only in 57.9% of the blood donors. The titers were quite low in general. The results are discussed from the point of view of the immunologic status of the patients.

[Possible relation between viruses and oromaxillofacial tumors. V. Demonstration of hemagglutination-inhibiting anti-BK virus antibodies in patients with tumors of the parotid gland]. / Relations possibles entre virus et tumeurs bucco-maxillo-faciales. Note V. Mise en évidence des anticorps inhibiteurs de l'hémagglutination anti-virus BK chez des malades porteurs de tumeurs de la glande parotide.

Anti-BK-virus hemagglutination inhibiting antibodies were revealed in 81.8% of the patients with parotid gland tumors. Results of the investigations conducted on oromaxillofacial tumors including the parotid gland ones are discussed from the point of view of the presence of viral antigens (herpes-, SV40 and BK-viruses) and of specific antibodies. Possible implication of the papova viruses in the etiopathogenesis of the parotid gland tumors in humans are also discussed.

Virus - tumor cell relationships. In vivo cocultivation of para-influenza type 1 (Sendai) virus and of Rous sarcoma virus (Schmidt-Ruppin strain) in mouse Ehrlich ascites carcinoma.

Co-infection of Ehrlich ascites carcinoma (EAC)-bearing mice with Sendai virus and Rous sarcoma virus (RSV) did not result in the formation of complete RSV. Sendai virus could be, however, propagated in this system over 8 serial passages. As demonstrated by immunofluorescence and complement fixation reactions, antigens specific to each virus were synthesized in EAC cells following either single or mixed virus infection. The virus progens also contained antigenic fractions incorporated from the host cell. The incomplete progens synthesized when RSV inoculation preceded that of Sendai virus possessed three polypeptide fractions characteristic of Sendai virus and one RSV-specific fraction.

Effect of homologous tumor DNA on the evolution of SV40-induced hamster sarcoma.

DNA extracted from SV40-induced hamster sarcoma (SV40--HS DNA) increased the survival length of animals carrying the homologous tumor and--in some cases--inhibited the development of the tumor. The efficacy of the preparation was directly proportional to the number of administrations; it did not necessarily depend on the amount of SV40--HS DNA per dose. SV40 DNA had no favourable effect on the evolution of the SV40-induced tumor, which suggests that viral DNA does not represent the active component of the SV40--HS DNA preparations. Some possible mechanisms of the effect of homologous tumor preparations are discussed.

Investigations on the presence of papova virus in certain forms of human cancer. Note 2. Brain tumors.

Two serially transmissible tumors (metastatic lymphosarcomas) were induced in the hamster by inoculation of human brain tumor material--tissue homogenate from a malignized fibroma or DNA extracted from a meningioma. SV40 V antigen was made evident by indirect immunofluorescence in 4 out of 18 human tumors, while SV40 T antigen could only be demonstrated in the tumors experimentally induced in hamsters. Antibodies to SV40 T antigen were detected in 12 out of 60 patients with different tumors, in 1 out of 40 blood donors and in 7 out of 18 hamsters carrying experimentally induced tumors.

Transformation of human diploid cells by adenovirus type 4 irradiated with ultraviolet light.

Inoculation of ultraviolet (UV)-irradiated adenovirus type 4 (Ad4) led to in vitro transformation of human diploid cells (HDC). Two transformed cell lines could be established: cell line H 1418, from HDC inoculated with the 10(-3) dilution of Ad4 UV-irradiated for 20 min at a distance of 20 cm, co-cultivated with uninfected HDC, and cell line H 1557, from HDC inoculated with the 10(-2) dilution of Ad4 irradiated at the same distance for 12 min. Both transformed cell lines were resistant to superinfection with homologous virus. Virus-specific antigen could be made evident by the indirect immunofluorescence technique in the nuclei of both H 1418 and H 1557 cells.

Virus--tumor host cell relationships. In vivo cocultivation of adenovirus type 5 and of SV40 in mouse Ehrlich ascites carcinoma.

Mouse Ehrlich ascites carcinoma (EAC) cells proved to be a semipermissive substrate for in vivo cultivation of adenovirus 5 (Ad5) and SV40. The multiplication of SV40 in EAC cells was facilitated by the coinfection with Ad5. As demonstrated by ID and EID reactions, the virus progens isolated at the first passage after the mixed infection of EAC cells with Ad5 and SV40 possess an antigenic mosaic with fractions characteristic of the parental viruses and of the cell substrate in which they had cultivated in vitro and in vivo. The progens gave positive seroneutralization and complement fixation reactions only with antiserum to SV40.

Investigations on the presence of antibodies to papova viruses in patients with different forms of cancer and in other categories of patients or apparently healthy subjects. Note I. Neutralizing antibodies to SV-40 in the cerebrospinal fluid of patients with brain tumors and chronic neurological diseases.

Neutralizing antibodies to SV-40 were detected in cerebrospinal fluid samples from 16 out of 43 patients with brain tumors and in 6 out of 20 patients with different nonmalignant chronic neurological diseases. The patients' age excluded the correlation with a vaccine-associated or occupational contact with SV-40. The results ascertain the occurrence of SV-40 or of an antigenically related virus in the population of Romania.

Incidence of viral antibodies in patients with various forms of cancer.

The results of over 13,500 serological reactions performed in about 3,400 human sera collected from patients with various forms of cancer and from apparently healthy subjects have shown that the humoral immune reactivity of cancer patients as regards their viral antibody response is similar to that of apparently healthy subjects (blood donors or workers exposed to the risk of occupational contact with animal tumor viruses). The authors also remark the presence in the population of antibodies to some viruses with oncogenic potential proved so far only for mammals (adenovirus, SV-40, RSV) or to ubiquitous viruses (e.g. herpes virus) whose transforming activity has been demonstrated for several cell types in vitro and is suspected for some human tumors in vivo.

The presence of complement fixing antibodies to the avian group-specific ("gs") sarcoma-leukosis antigen in the human population and in cancer patients.

Antibodies to the avian group-specific "gs" sarcoma-leukosis antigen were made evident by complement fixation reaction in human sera collected from apparently healthy subjects and from patients with different forms of cancer and non-neoplastic diseases. The number of sera investigated was of 2,123. The possible mechanisms that might account for this paraimmune response of the human organism and the prospects of developing prophylactic steps against cancer are discussed.

Investigations on the incidence of complement fixing antibodies to the avian group-specific ("gs") sarcoma-leukosis antigen in fowl farm workers.

The presence of complement fixing antibodies to the avian "gs" sarcoma-leukosis antigen is reported in the personnel of five different fowl farms. Seroconversion was observed in the workers from one of the farms, where the initial antibody incidence was very low.